SCHEMBL17239

SCHEMBL17239

Nc1ccc2cnc3cccc(N)c3c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
POLB P06746 2/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
PTBP1 P26599 1/20 0.43
RCE1 Q9Y256 1/20 0.43
MET P08581 1/20 0.43
HTR3A P46098 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
GPR3 P46089 1/20 0.40
EGFR P00533 4/20 0.40
TYMS P04818 1/20 0.40
HSD17B10 Q99714 3/20 0.39
MEN1 O00255 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL841678 0.82 KDM4E (0.57) KDM4EALDH1A1KMT2ALMNANPC1
SCHEMBL11516897 0.77 KDM4E (0.64) KDM4EALDH1A1KMT2ALMNANPC1
SCHEMBL27997404 0.76 ALDH1A1 (0.50) KDM4EALDH1A1KMT2ALMNANPC1
SCHEMBL14742590 0.76 CTDSP1 (0.57) KDM4EALDH1A1KMT2ALMNANPC1
SCHEMBL21409753 0.73 KMT2A (0.45) KDM4EALDH1A1KMT2ALMNANPC1
SCHEMBL19445131 0.72 KDM4E (0.54) KDM4EALDH1A1KMT2ALMNANPC1
SCHEMBL8628036 0.71 KMT2A (0.70) KDM4EALDH1A1KMT2ALMNANPC1
Hydrochloric Acid SCHEMBL28888962 0.70 KMT2A (0.68) KDM4EALDH1A1KMT2ALMNANPC1
SCHEMBL6151918 0.69 KDM4E (0.64) KDM4EALDH1A1KMT2ALMNANPC1
SCHEMBL29405526 0.69 CTDSP1 (0.63) KDM4EALDH1A1KMT2ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009032172-A2 PLATINUM COMPOSITIONS AS TREATMENT FOR OCT-RELATED CANCERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2009-03-12 WO claimed
US-12544491-B2 In situ forming hemostatic foam implants ARSENAL MEDICAL, INC. (US) 2026-02-10 US disclosed
EP-3922187-B1 IN SITU FORMING HEMOSTATIC FOAM IMPLANTS ARSENAL MEDICAL INC (US) 2026-01-07 EP disclosed
US-20250242063-A1 METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF LANTHEUS MEDICAL IMAGING, INC. (US) 2025-07-31 US disclosed
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-29 US disclosed
US-20250171398-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-29 US disclosed
US-20250170282-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-29 US disclosed
US-12300434-B2 High yield storage materials PolyJoule, Inc. (US) 2025-05-13 US disclosed
US-12243664-B2 Triazine-based polymer PolyJoule, Inc. (US) 2025-03-04 US disclosed
US-20250019381-A1 PROCESS FOR THE SYNTHESIS OF 6-((3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-3-(TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-a]PYRAZIN-8-ONE CARDURION PHARMACEUTICALS, INC. 2025-01-16 US disclosed
WO-2011109276-A1 EPOXIDATION CATALYSTS MASSACHUSSETS INSTITUTE OF TECHNOLOGY (US) 2011-09-09 WO disclosed
US-20110202016-A1 SYSTEMS AND METHODS RELATING TO POLYMER FOAMS ARSENAL MEDICAL, INC. (US) 2011-08-18 US disclosed
WO-2011097649-A2 METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF LANTHEUS MEDICAL IMAGING, INC. (US) 2011-08-11 WO disclosed
US-20110118469-A1 CONTINUOUS FLOW SYNTHESIS OF AMINO ALCOHOLS USING MICROREACTORS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2011-05-19 US disclosed
WO-2011056929-A1 CONTINUOUS FLOW SYNTHESIS OF AMINO ALCOHOLS USING MICROREACTORS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2011-05-12 WO disclosed
US-20100316998-A1 METHODS AND COMPOSITIONS FOR EMPIRICAL SELECTION OF DRUGS OR OTHER MOLECULES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2010-12-16 US disclosed
WO-2010047765-A2 NANOSTRUCTURES FOR DRUG DELIVERY MASSACHUSSETTS INSTITUTE OF TECHNOLOGY (US) 2010-04-29 WO disclosed
WO-2010027428-A1 PLATINUM ( IV) COMPLEXES FOR USE IN DUAL MODE PHARMACEUTICAL THERAPY MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2010-03-11 WO disclosed
WO-2009032172-A2 PLATINUM COMPOSITIONS AS TREATMENT FOR OCT-RELATED CANCERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2009-03-12 WO disclosed
US-20080138292-A1 Sensors for fluorescence and magnetic resonance imaging MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 KDM4E 4378/4885ALDH1A1 3040/4885KMT2A 4341/4885
US-20250242063-A1 METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF TNNI3, FABP3, MPI KDM4E 3124/4885ALDH1A1 1208/4885KMT2A 4371/4885
US-20100316998-A1 METHODS AND COMPOSITIONS FOR EMPIRICAL SELECTION OF DRUGS OR OTHER MOLECULES ABCG2, MRPS34, PIGO KDM4E 4739/4885ALDH1A1 2126/4885KMT2A 4845/4885
US-20110118469-A1 CONTINUOUS FLOW SYNTHESIS OF AMINO ALCOHOLS USING MICROREACTORS ADH1C, ADH1A, ADH5 KDM4E 1181/4885ALDH1A1 34/4885KMT2A 651/4885
US-12544491-B2 In situ forming hemostatic foam implants F9, F12, F2 KDM4E 2509/4885ALDH1A1 3891/4885KMT2A 4236/4885
US-20250171398-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 KDM4E 2553/4885ALDH1A1 732/4885KMT2A 2531/4885
US-20080138292-A1 Sensors for fluorescence and magnetic resonance imaging CA2, SLC30A6, SLC39A3 KDM4E 4147/4885ALDH1A1 3462/4885KMT2A 3742/4885
US-12243664-B2 Triazine-based polymer PARG, TPR, PARN KDM4E 2943/4885ALDH1A1 1852/4885KMT2A 992/4885
US-20250170282-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 KDM4E 3637/4885ALDH1A1 2699/4885KMT2A 3430/4885
US-20250019381-A1 PROCESS FOR THE SYNTHESIS OF 6-((3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-3-(TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-a]PYRAZIN-8-ONE CDK8, PRMT8, DHPS KDM4E 869/4885ALDH1A1 2427/4885KMT2A 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.